Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GMP comment period extended

This article was originally published in The Tan Sheet

Executive Summary

The public comment period on a proposed rule allowing exemptions from 100 percent identity testing requirements in the dietary supplements good manufacturing practices final rule is extended to Oct. 24, FDA says in a Sept. 17 Federal Register notice. FDA responded to requests from parties calling for more time to comment. FDA published the testing exemption IFR and the GMP final rule in June (1"The Tan Sheet" June 25, 2007, p. 3)...

You may also be interested in...



Dingell Questions Ingredient Testing Exemption Rule, Cites Supply Climate

House Energy and Commerce Committee Chairman John Dingell is questioning allowing exemptions from 100 percent identity testing requirements for dietary supplement ingredients in light of mounting food safety issues

Yes For Shionogi But No For Lilly In Latest EMA Recommendations

The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.

UK To Seek Only Limited Regulatory Alignment With EU

Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.

Topics

UsernamePublicRestriction

Register

PS100909

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel